We did a systematic review and meta-analysis of trials of treatment for rifampicin-susceptible tuberculosis to evaluate the representativeness of participants compared with characteristics of the global population of people with tuberculosis, and the a...
In this 14-day trial, quabodepistat plus delamanid plus bedaquiline, a novel three-drug combination, appeared to be safe, well tolerated, and provided robust early bactericidal activity in adults with drug-susceptible pulmonary tuberculosis. Further ev...
For the first time in 60 years, the tuberculosis drug development pipeline promises novel drugs and treatment strategies for safe, well tolerated, highly efficacious, and short treatment for tuberculosis, the leading cause of death from a curable infec...
The re-election of Donald Trump as the 47th president of the USA has raised concerns among health-care professionals and public health experts about the future of global health and pandemic preparedness.1 Trump's COVID-19 response was marked by unclear...
The COVID-19 pandemic reminded us of what vaccines can do to prevent life-threatening diseases.1 Respiratory infections such as influenza, COVID-19, respiratory syncytial virus (RSV), and pneumococcal disease contribute significantly to global morbidit...
Brazilian researchers published a Correspondence piece listing some “key lessons” learned after the Zika aftermath in Brazil.1 In the last decade, Brazil has been the epicentre of two health emergencies, Zika and COVID-19, with particular consequences ...
Coadministered mRNA-1345 plus SIIV4 or mRNA-1273.214 vaccines had acceptable safety profiles and elicited mostly non-inferior immune responses compared to individual vaccines in adults aged 50 years or older; only the seroresponse rate difference in nA...
KP.3, a subvariant of JN.1, has rapidly emerged as the dominant strain of SARS-CoV-2 in several countries, and has been designated as a Variant Under Monitoring. Previous studies indicate that the unique Q493E substitution in KP.3 Spike glycoprotein en...
The 2024 WHO Global Tuberculosis Report1 presents a stark reminder of the devastating effect of tuberculosis. In 2023, tuberculosis caused 1·25 million deaths, making it once again the leading cause of death from an infectious disease. Tuberculosis con...
Bacterial sexually transmitted infections (STIs) are a considerable burden among people with HIV and users of HIV pre-exposure prophylaxis (PrEP).1–3 Doxycycline post-exposure prophylaxis (DoxyPEP) is a pharmacological intervention, the efficacy of whi...
WHO's roadmap for Nipah virus research priorities (2024–29) outlines ambitious milestones for advancing diagnostics, therapeutics, and vaccines.1 Although the roadmap signifies progress against Nipah virus, it also exposes inequities in global health g...
Our results confirm that the novel OROV reassortant lineage spread from the Amazon to other regions in early 2024, successfully establishing local transmission. The fact that outbreaks were observed in small municipalities, instead of large urban centr...
Our results confirm that the novel OROV reassortant lineage spread from the Amazon to other regions in early 2024, successfully establishing local transmission. The fact that outbreaks were observed in small municipalities, instead of large urban centr...
The 2023–24 Oropouche virus (OROV) outbreak in the Americas has raised public health concerns due to unprecedented numbers of confirmed cases reaching almost 10 000 reported in the WHO region of the Americas, including at least two deaths and potential...
The 2023–24 Oropouche virus (OROV) outbreak in the Americas has raised public health concerns due to unprecedented numbers of confirmed cases reaching almost 10 000 reported in the WHO region of the Americas, including at least two deaths and potential...
Mass deployment of long-lasting insecticide-treated mosquito nets, indoor residual spraying, and artemisinin-based drugs have led to remarkable declines of malaria since the early 2000s. However, progress is stalling, probably because of emerging resis...